LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) EBIT

The latest EBIT for LSBPW is $-200M as of March 2024. That compares with $-9.4M in the prior-year period — down 2021.5% year over year. That is below the sector sector average of $-63M. Investors often review this figure alongside LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, LSBPW's EBIT moved from $-9.4M to $-200M — a 2021.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s operating scale or balance-sheet position.

Against its sector companies, LSBPW currently prints $-200M for EBIT, while the sector average sits near $-63M. That is roughly 219.0% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s growth, margins, and balance sheet.

A EBIT figure of $-200M for LSBPW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting LSBPW's EBIT ($-200M), review year-over-year change from $-9.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.